Are FDC latest results good or bad?

FDC, a midcap player in the Pharmaceuticals and Biotechnology sector, has reported its financial results for the quarter ending March 2025, which reflect notable challenges in its performance. The Profit Before Tax (PBT) for this quarter was recorded at Rs 37.23 crore, indicating a significant decline of 44.2% compared to the average PBT of Rs 66.72 crore from the previous four quarters. Similarly, the Profit After Tax (PAT) fell to Rs 38.67 crore, down 43.6% from the average PAT of Rs 68.60 crore over the same period.
Net sales also experienced a downturn, totaling Rs 491.89 crore, which represents a 5.3% decline from the average net sales of Rs 519.57 crore in the preceding four quarters. However, when looking at the quarterly performance, there was a reported growth in net sales of 5.99% compared to the previous quarter, with net profit showing a growth of 4.40%.

The overall financial score for FDC has seen an adjustment, indicating a slight improvement in its evaluation. Despite this revision, the near-term trends for PBT, PAT, and net sales remain negative, highlighting ongoing operational challenges for the company.